Corbus Pharmaceuticals reports a smaller-than-expected Q1 loss and $138.2 million in cash, extending its funding runway into 2028.
Corbus Pharmaceuticals posted a Q1 GAAP loss of $1.23 per share, beating expectations by $0.02. The narrower loss reflects ongoing cost management amid clinical development efforts.
The company reported $138.2 million in cash, cash equivalents, and investments as of March 31, 2026. This liquidity position is projected to fund operations into 2028 based on current plans and expenditures.
Shares showed limited movement in after-hours trading as investors weighed the improved cash runway against the persistent loss.